CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration
Aug 02, 2021
CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
Jul 15, 2021
CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor
May 12, 2021
Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases
Apr 29, 2021
CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms
Apr 27, 2021
First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore
Mar 10, 2021
CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration
Feb 26, 2021